Cargando…

Suicide gene therapy for the treatment of high-grade glioma: past lessons, present trends, and future prospects

Suicide gene therapy has represented an experimental cancer treatment modality for nearly 40 years. Among the various cancers experimentally treated by suicide gene therapy, high-grade gliomas have been the most prominent both in preclinical and clinical settings. Failure of a number of promising su...

Descripción completa

Detalles Bibliográficos
Autores principales: Hossain, Jubayer A, Marchini, Antonio, Fehse, Boris, Bjerkvig, Rolf, Miletic, Hrvoje
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212909/
https://www.ncbi.nlm.nih.gov/pubmed/32642680
http://dx.doi.org/10.1093/noajnl/vdaa013
_version_ 1783531696602218496
author Hossain, Jubayer A
Marchini, Antonio
Fehse, Boris
Bjerkvig, Rolf
Miletic, Hrvoje
author_facet Hossain, Jubayer A
Marchini, Antonio
Fehse, Boris
Bjerkvig, Rolf
Miletic, Hrvoje
author_sort Hossain, Jubayer A
collection PubMed
description Suicide gene therapy has represented an experimental cancer treatment modality for nearly 40 years. Among the various cancers experimentally treated by suicide gene therapy, high-grade gliomas have been the most prominent both in preclinical and clinical settings. Failure of a number of promising suicide gene therapy strategies in the clinic pointed toward a bleak future of this approach for the treatment of high-grade gliomas. Nevertheless, the development of new vectors and suicide genes, better prodrugs, more efficient delivery systems, and new combinatorial strategies represent active research areas that may eventually lead to better efficacy of suicide gene therapy. These trends are evident by the current increasing focus on suicide gene therapy for high-grade glioma treatment both in the laboratory and in the clinic. In this review, we give an overview of different suicide gene therapy approaches for glioma treatment and discuss clinical trials, delivery issues, and immune responses.
format Online
Article
Text
id pubmed-7212909
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-72129092020-07-07 Suicide gene therapy for the treatment of high-grade glioma: past lessons, present trends, and future prospects Hossain, Jubayer A Marchini, Antonio Fehse, Boris Bjerkvig, Rolf Miletic, Hrvoje Neurooncol Adv Review Suicide gene therapy has represented an experimental cancer treatment modality for nearly 40 years. Among the various cancers experimentally treated by suicide gene therapy, high-grade gliomas have been the most prominent both in preclinical and clinical settings. Failure of a number of promising suicide gene therapy strategies in the clinic pointed toward a bleak future of this approach for the treatment of high-grade gliomas. Nevertheless, the development of new vectors and suicide genes, better prodrugs, more efficient delivery systems, and new combinatorial strategies represent active research areas that may eventually lead to better efficacy of suicide gene therapy. These trends are evident by the current increasing focus on suicide gene therapy for high-grade glioma treatment both in the laboratory and in the clinic. In this review, we give an overview of different suicide gene therapy approaches for glioma treatment and discuss clinical trials, delivery issues, and immune responses. Oxford University Press 2020-02-06 /pmc/articles/PMC7212909/ /pubmed/32642680 http://dx.doi.org/10.1093/noajnl/vdaa013 Text en © The Author(s) 2020. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Hossain, Jubayer A
Marchini, Antonio
Fehse, Boris
Bjerkvig, Rolf
Miletic, Hrvoje
Suicide gene therapy for the treatment of high-grade glioma: past lessons, present trends, and future prospects
title Suicide gene therapy for the treatment of high-grade glioma: past lessons, present trends, and future prospects
title_full Suicide gene therapy for the treatment of high-grade glioma: past lessons, present trends, and future prospects
title_fullStr Suicide gene therapy for the treatment of high-grade glioma: past lessons, present trends, and future prospects
title_full_unstemmed Suicide gene therapy for the treatment of high-grade glioma: past lessons, present trends, and future prospects
title_short Suicide gene therapy for the treatment of high-grade glioma: past lessons, present trends, and future prospects
title_sort suicide gene therapy for the treatment of high-grade glioma: past lessons, present trends, and future prospects
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212909/
https://www.ncbi.nlm.nih.gov/pubmed/32642680
http://dx.doi.org/10.1093/noajnl/vdaa013
work_keys_str_mv AT hossainjubayera suicidegenetherapyforthetreatmentofhighgradegliomapastlessonspresenttrendsandfutureprospects
AT marchiniantonio suicidegenetherapyforthetreatmentofhighgradegliomapastlessonspresenttrendsandfutureprospects
AT fehseboris suicidegenetherapyforthetreatmentofhighgradegliomapastlessonspresenttrendsandfutureprospects
AT bjerkvigrolf suicidegenetherapyforthetreatmentofhighgradegliomapastlessonspresenttrendsandfutureprospects
AT miletichrvoje suicidegenetherapyforthetreatmentofhighgradegliomapastlessonspresenttrendsandfutureprospects